Core Insights - Eisai Co., Ltd. and Biogen Inc. announced that their anti-Aβ protofibril antibody LEQEMBI has been included in China's "Commercial Insurance Innovative Drug List," enhancing access to early Alzheimer's Disease treatment in the country [1][2] Group 1: Product and Market Impact - The inclusion of LEQEMBI in the Commercial Insurance Innovative Drug List is a significant step towards improving access to innovative medicines in China, addressing the coverage gap between basic reimbursement and innovative treatments [2] - Eisai estimates that there were 17 million patients with mild cognitive impairment or mild dementia due to Alzheimer's Disease in China in 2024, a number expected to rise with the aging population [3] - LEQEMBI was launched in China in June 2024 and is currently available in the private market [3] Group 2: Development and Collaboration - Eisai leads the global development and regulatory submissions for LEQEMBI, with both Eisai and Biogen co-commercializing and co-promoting the product [4][9] - The drug is a result of a strategic research alliance between Eisai and BioArctic, targeting aggregated soluble and insoluble forms of amyloid-beta [7][10] - LEQEMBI has been approved in 51 countries and is under regulatory review in 9 additional countries, with various dosing regimens approved [7] Group 3: Clinical Studies and Research - Ongoing clinical studies include the Phase 3 AHEAD 3-45 study for individuals with preclinical Alzheimer's Disease, funded by the National Institute on Aging and conducted in partnership with the Alzheimer's Clinical Trial Consortium [8] - The Tau NexGen clinical study for Dominantly Inherited Alzheimer's Disease is also ongoing, incorporating lecanemab as a key therapy [8]